MERTK-expressing monocytes represented 14.4% of all circulating monocytes in patients with AD and even 35.7% in ACLF, respectively, and showed dampened innate immune responses to LPS in close association with clinical disease severity scores and the need for transplantation or death (Bernsmeier et al., 2015b). The gene discussed is MERTK; the disease is Alzheimer disease.